Virtus Investment Advisers’s ADMA Biologics ADMA Stock Holding History

Virtus Investment Advisers’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.19M	Buy	141,642 +98,959	+232%	+$902K	0.28%	183
2026 Q1	$385K	Buy	42,683 +8,132	+24%	+$128K	0.11%	250
2025 Q4	$630K	Buy	34,551 +13,977	+68%	+$236K	0.17%	215
2025 Q3	$302K	Hold	20,574	–	–	0.09%	240
2025 Q2	$375K	Buy	20,574 +1,344	+7%	+$27.4K	0.13%	232
2025 Q1	$382K	Buy	19,230 +4,250	+28%	+$73.5K	0.1%	215
2024 Q4	$257K	Sell	14,980 -62,917	-81%	-$1.18M	0.2%	161
2024 Q3	$1.56M	Buy	+77,897	New	+$1.21M	1.22%	13
2024 Q2	–	Sell	-157,268	Closed	-$1.32M	–	7
2024 Q1	$1.04M	Hold	157,268	–	–	0.74%	31
2023 Q4	$711K	Buy	157,268 +84,373	+116%	+$312K	0.53%	45
2023 Q3	$261K	Buy	72,895 +12,462	+21%	+$48K	0.18%	141
2023 Q2	$223K	Buy	+60,433	New	+$224K	0.15%	177

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Virtus Investment Advisers's ADMA Position: Q2 2026 in Review

Virtus Investment Advisers increased its ADMA Biologics (ADMA) stake by 232% in Q2 2026, buying an estimated $902K and bringing the position to 141,642 shares worth $1.19M. The position accounts for 0.28% of the portfolio, ranked #183.

Virtus Investment Advisers first reported a position in ADMA in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.56M in Q3 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Virtus Investment Advisers held 141,642 shares of ADMA Biologics worth $1.19M as of Q2 2026.
Virtus Investment Advisers bought 98,959 ADMA Biologics shares in Q2 2026, an estimated $902K.
ADMA Biologics made up 0.28% of Virtus Investment Advisers's portfolio in Q2 2026, its #183 holding.
Virtus Investment Advisers first reported a position in ADMA Biologics in Q2 2023 and has held it in 12 quarters since.
Virtus Investment Advisers's ADMA Biologics position peaked at $1.56M in Q3 2024.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.